Medicine
Beovu 6 mg/0.05 mL injection
Beovu 6 mg/0.05 mL injection is a prescription medicine containing Brolucizumab for intravitreal use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store BEOVU in the outer carton to protect from light.
Key facts
- Active ingredient (INN)
- Brolucizumab
- Brand
- Beovu
- Strength
- 6 mg/0.05 mL
- Dosage form
- Injection
- Route
- Intravitreal
- Packs
- 1 syringe of 0.05 mL
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store BEOVU in the outer carton to protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- S01 Eye medicines
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 7 October 2019
- Identifiers
- RxCUI 2204920, 2204925, 2602276 +1DailyMed set ID 5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3dNDC 0078-0827Application BLA761125
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / .05 mL in 1 syringe, glass | 0078-0827-60 | Novartis Pharmaceuticals | 9 March 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Brolucizumab is a prescription medicine indicated for the treatment of bEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of, among other approved uses. It is available as injection for intravitreal use. MedsAcross supplies Brolucizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BrolucizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- BEOVU prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Beovu: European public assessment report (EPAR) · European Medicines Agency
Need Beovu 6 mg/0.05 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.